EUVIMEDAtrasti EUVIMED
EUVIMED · CrossrefJournal

Lung Cancer

ISSN 0169-5002 · Elsevier BV

Latest articles

  1. Efficacy and safety of primary granulocyte colony-stimulating factor prophylaxis in patients with small-cell lung cancer receiving first-line platinum–etoposide plus a programmed death-ligand 1 inhibitor: A multicenter retrospective observational study (G-GUARD; TORG-TG2504)

    Shuhei Teranishi, Yuki Misumi, Takuma Ishihara, Yuta Yamanaka, Daiki Murata, Tomofumi Hirose, Ryosuke Ochiai, Kento Takagi, Yuko Higashi, Yusuke Hamakawa, Satoshi Ikeda, Naoki Furuya, Yoshiro Nakahara, Satoru Miura, Katsuhiko Naoki

    Published: 2026-12DOI: 10.1016/j.lungcan.2026.109671

  2. Coexistence of Osimertinib-Resistant and Osimertinib-Sensitive cell states in an EGFR-Mutant NSCLC model derived at osimertinib resistance

    Ilaria C. Chillico, Mariateresa Frascino, Giorgia Protopapa, Francesca Ruzzi, Elena Nironi, Francesca Giunchi, Damiano Pistone, Elisa Gruppioni, Annalisa Altimari, Marzia Rossato, Giacomo Lora, Francesco Agustoni, Mattia Lauriola, Andrea Ardizzoni, Patrick L.S. Michel, Sofia Fini, Pier-Luigi Lollini, Stefania Angelicola, Francesco Gelsomino, Arianna Palladini

    Published: 2026-12DOI: 10.1016/j.lungcan.2026.109680

  3. Characteristics and outcomes of patients with advanced or metastatic non–small cell lung cancer harboring a HER2-activating mutation: a real-world retrospective cohort study using a US clinico-genomic database

    Xiuning Le, Christos Chouaid, Fernando Lopez-Rios, Mei Sheng Duh, Maral DerSarkissian, Vadim Bernard-Gauthier, Jihong Zong, Zdravko Vassilev, Orsolya Lunacsek, Angela Lax, Andreas Schlicker, Rose Chang, Megan Pinaire, Naiyu Chen, Qayyim Said

    Published: 2026-11DOI: 10.1016/j.lungcan.2026.109677

  4. Navitoclax overcomes epithelial–mesenchymal transition-associated resistance in ALK-positive non-small cell lung cancer with rapid disease progression during alectinib treatment

    Tomoka Nishimura, Shuta Tomida, Tadahiro Kuribayashi, Takaaki Tanaka, Taku Noumi, Masataka Taoka, Shunta Mori, Jun Nishimura, Ayako Morita, Kenji Takada, Naofumi Hara, Hiromi Watanabe, Kiichiro Ninomiya, Hisao Higo, Toshio Kubo, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Yoshinobu Maeda, Yosuke Togashi, Go Makimoto

    Published: 2026-11DOI: 10.1016/j.lungcan.2026.109681

  5. Decoding immune signatures driving brain metastases in stage III non-small cell lung cancer

    Shiva Najjary, Disha Vadgama, Johan M. Kros, Jan H. von der Thüsen, Dirk De Ruysscher, Harry Groen, José Belderbos, Gerben G. Bootsma, Ben van den Borne, Anne-Marie Dingemans, Judith Herder, Tjeerd Haitjema, Katrien De Jaeger, Cordula Pitz, Hans Smit, Jos Stigt, Ernest Vonk, Marcel Westenend, Sherif Y. El Sharouni, Ernst-Jan Speel, Dana A.M. Mustafa, Lizza E.L. Hendriks

    Published: 2026-11DOI: 10.1016/j.lungcan.2026.109692

  6. Patient-reported outcomes from the phase 3 IMforte study of first-line maintenance treatment with lurbinectedin + atezolizumab versus atezolizumab in patients with extensive-stage small cell lung cancer

    Stephen V. Liu, Luis Paz-Ares, Martin Reck, Hossein Borghaei, Roy S. Herbst, Muhammet Bekir Hacioğlu, Atike Gokcen Demiray, Adam Płużański, Giannis Mountzios, Athanasios Kotsakis, Stefan Hammerschmidt, Gabriella Gálffy, Eleni Karapanagiotou, Siobhan Connor-Ahmad, Carla Mamolo, Ya-Chen Lin, Jonathon Gable, Kamalnayan Bhatt, George Cai, Solange Peters

    Published: 2026-11DOI: 10.1016/j.lungcan.2026.109695

Volumes

2026 · 6762025 · 6552024 · 4692023 · 4612022 · 4232021 · 5462020 · 6062019 · 5932018 · 5662017 · 4682016 · 4592015 · 4782014 · 5142013 · 6592012 · 6132011 · 5472010 · 4242009 · 6102008 · 3592007 · 4502006 · 5072005 · 1,8052004 · 3572003 · 1,5272002 · 3012001 · 2962000 · 1,0641999 · 2381998 · 2781997 · 1,3171996 · 8281995 · 1,2111994 · 1,5951993 · 5491992 · 2701991 · 1,1451990 · 3311989 · 4661988 · 511987 · 387

Jūsų darbui tinkamos žinios.

Nuo nemokamos pradžios ir asmeninės literatūros paieškos iki viso Research Suite.

Peržiūrėti tarifus →

Ar įtraukti visi leidėjų pilnieji tekstai?

Ne. Bibliografiniai įrašai, santraukos ir pilnieji tekstai yra skirtingas turinys. Ar pilnasis tekstas prieinamas, priklauso nuo šaltinio, Open Access ir jūsų turimų licencijų. EUVIMED planas nepakeičia papildomų leidėjų teisių.